secwatch.observer — SEC 8-K summary
======================================

Issuer:     Totaligent, Inc. (TGNT)
CIK:        0000846377
Form:       8-K
Filed at:   2026-02-12T23:59:59+00:00
Accession:  0001477932-26-000765
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.55
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Totaligent enters acqui-hire LOI with Aetherium Medical; 10% equity stake, no cash
--------------------------------------------------------------------------------

- Acquiring Aetherium's team, IP, business plan in exchange for 10% of Totaligent's outstanding common stock as restricted preferred.
- New wholly owned subsidiary Aetherium Medical LLC formed; Assets contributed with no cash consideration at closing.
- Ivan Klarich, Aetherium's CEO, appointed Managing Director of the subsidiary.
- Target closing March 5, 2026; exclusivity through April 5, 2026; definitive agreements to follow.
- Equity subject to milestone-based vesting, 15% escrow holdback for 12 months, and repurchase rights.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/846377/000147793226000765/0001477932-26-000765-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/846377/000147793226000765/totaligent_8k.htm
  HTML page:      https://secwatch.observer/filing/0001477932-26-000765

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer